Significance of the drug-induced lymphocyte stimulation test for various oral mesalamines in ulcerative colitis with mesalamine intolerance
PLOS One · 2025
DOI: 10.1371/journal.pone.0334969 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Akira Madarame und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Tokyo Medical University Hospital, Tokyo, Japan. Hauptthemen laut MEDLINE: Mesalamine, Colitis, Ulcerative, Anti-Inflammatory Agents, Non-Steroidal, Lymphocyte Activation. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
This study aimed to determine if the drug-induced lymphocyte stimulation test (DLST) for various oral mesalamines can diagnose mesalamine intolerance and predict the success of retreatment in patients with adverse events (AEs) due to the first oral 5-aminosalicylate (5-ASA) formulations administered. Data from patients with ulcerative colitis who experienced AEs after administration of the first oral 5-ASA and underwent DLSTs for two or more types of mesalamine, including the first oral 5-ASA were retrospectively analyzed. Mesalamine intolerance was defined as AEs within 6 months of starting the first oral 5-ASA and the inability to take oral mesalamine. Clinical characteristics, symptoms, type of first oral 5-ASA, DLST results, and the efficacy of retreatment with oral mesalamine were compared. The DLST for the first oral 5-ASA (F-DLST), highest DLST among the different oral mesalamine types (H-DLST), and mean DLST (M-DLST) were analyzed. Twenty-eight patients (median age 39 years, 57.1% male) were eligible; six patients were tolerant to oral mesalamine and22 were intolerant. Positive F-DLST (odds ratio [OR], 2.300; p = 0.002), positive M-DLST (OR, 2.667; p = 0.007), and older age at diagnosis (median 24.5 vs. 41.5; p = 0.006) were associated with mesalamine intolerance. Fourteen of the 28 patients underwent mesalamine retreatment. Higher F-DLST (median 88.0 vs. 174.0; p = 0.026), M-DLST (median 118.5 vs. 170.3; p = 0.040), and older age at diagnosis (median 24.5 vs. 39.0; p = 0.033) were associated with retreatment failure for oral mesalamine. DLSTs for various oral mesalamine formulations may be useful in predicting mesalamine intolerance and retreatment outcomes. However, their clinical utility should be interpreted with caution due to the risk of false-positive and false-negative results.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology and Hepatology, Tokyo Medical University Hospital, Tokyo, Japan.
ORCID-Profile: Akira Madarame
Zitieren
APA
Madarame, A., Fukuzawa, M., Uchida, K., Ichimiya, T., Naito, S., Yamauchi, Y., Morise, T., Kagawa, Y., Muramatsu, T., & Itoi, T. (2025). Significance of the drug-induced lymphocyte stimulation test for various oral mesalamines in ulcerative colitis with mesalamine intolerance. PLOS One. https://doi.org/10.1371/journal.pone.0334969
Vancouver
Madarame A, Fukuzawa M, Uchida K, Ichimiya T, Naito S, Yamauchi Y, et al. Significance of the drug-induced lymphocyte stimulation test for various oral mesalamines in ulcerative colitis with mesalamine intolerance. PLOS One. 2025. doi:10.1371/journal.pone.0334969
BibTeX
@article{Madarame2025,
author = {Madarame, Akira and Fukuzawa, Masakatsu and Uchida, Kumiko and Ichimiya, Tadashi and Naito, Sakiko and Yamauchi, Yoshiya and Morise, Takashi and Kagawa, Yasuyuki and Muramatsu, Takahiro and Itoi, Takao},
title = {Significance of the drug-induced lymphocyte stimulation test for various oral mesalamines in ulcerative colitis with mesalamine intolerance},
journal = {PLOS One},
year = {2025},
doi = {10.1371/journal.pone.0334969}
}
EUVIMED